Veracyte, Inc. (VCYT) is a publicly traded Healthcare sector company. As of May 21, 2026, VCYT trades at $45.00 with a market cap of $3.31B and a P/E ratio of 40.34. VCYT moved +8.37% today. Year to date, VCYT is +3.58%; over the trailing twelve months it is +56.86%. Its 52-week range spans $22.61 to $50.71. Analyst consensus is buy with an average price target of $45.28. Rallies surfaces VCYT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in VCYT news today?
Veracyte Q1 EPS $0.52 on $139.1M Revenue Beats Forecast, Raises Guidance: Veracyte reported Q1 net income of $28.7 million, or $0.35 per share, with adjusted EPS of $0.52 on revenues of $139.1 million, surpassing analyst forecasts of $0.34 EPS and $130.5 million revenue. Management lifted full-year revenue guidance to $582–$592 million and analysts predict a 39% upside potential.
Veracyte Q1 EPS $0.52 on $139.1M Revenue Beats Forecast, Raises Guidance: Veracyte reported Q1 net income of $28.7 million, or $0.35 per share, with adjusted EPS of $0.52 on revenues of $139.1 million, surpassing analyst forecasts of $0.34 EPS and $130.5 million revenue. Management lifted full-year revenue guidance to $582–$592 million and analysts predict a 39% upside potential.
Does Rallies summarize VCYT news?
Yes. Rallies summarizes VCYT news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is VCYT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for VCYT. It does not provide personalized investment advice.
